Chimerix Inc (CMRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Chimerix Inc stock (CMRX) is currently trading at $8.54. Chimerix Inc PS ratio (Price-to-Sales) is 3778.70. Analyst consensus price target for CMRX is $8.53. WallStSmart rates CMRX as Sell.
- CMRX PE ratio analysis and historical PE chart
- CMRX PS ratio (Price-to-Sales) history and trend
- CMRX intrinsic value — DCF, Graham Number, EPV models
- CMRX stock price prediction 2025 2026 2027 2028 2029 2030
- CMRX fair value vs current price
- CMRX insider transactions and insider buying
- Is CMRX undervalued or overvalued?
- Chimerix Inc financial analysis — revenue, earnings, cash flow
- CMRX Piotroski F-Score and Altman Z-Score
- CMRX analyst price target and Smart Rating
Chimerix Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Chimerix Inc (CMRX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Chimerix Inc (CMRX) Key Strengths (2)
Revenue surging 1325.00% year-over-year
56.44% held by institutions, strong professional interest
Supporting Valuation Data
Chimerix Inc (CMRX) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 3778.7x annual revenue
Very expensive at 6.6x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Chimerix Inc (CMRX) Detailed Analysis Report
Overall Assessment
This company scores 25/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 1325.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (3778.70), Price/Book (6.58) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -56.20%, Operating Margin at -43074.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -56.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 1325.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CMRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CMRX's Price-to-Sales ratio of 3778.70x trades 718% above its historical average of 462.19x (94th percentile), historically expensive. The current valuation is 0% below its historical high of 3778.71x set in Apr 2025, and 143033% above its historical low of 2.64x in Nov 2023.
WallStSmart Analysis Synopsis
Data-driven financial summary for Chimerix Inc (CMRX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Chimerix Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 212,000 with 1325% growth year-over-year.
Key Findings
Revenue growing at 1325% YoY, reaching 212,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 8328% of revenue (18M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -19M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Chimerix Inc maintain 1325%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Chimerix Inc.
Bottom Line
Chimerix Inc is a high-conviction growth story with revenue accelerating at 1325% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 11:50:12 AM
About Chimerix Inc(CMRX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Chimerix, Inc., a developing-stage biopharmaceutical company, focuses on accelerating the advancement of various drugs that impact the lives of patients living with cancer and other serious diseases. The company is headquartered in Durham, North Carolina.